Abstract: This application discloses a head region recognition method performed at a computing device. The method includes: acquiring an input image; processing the input image using n cascaded neural network layers to obtain n sets of candidate recognition results of a head region, each of the n neural network layers outputting one respective set of candidate recognition results, the neural network layer being used for recognizing the head region according to a preset extraction box, sizes of extraction boxes used by at least two of the neural network layers being different, and n being a positive integer and n?2; and aggregating the n sets of candidate recognition results to obtain a final recognition result of the head region in the input image. Therefore, head regions with different sizes in the input image can be recognized, thereby improving recognition accuracy.

Abstract: Disclosed are devices capable of heterogeneous electrochemical catalysis. Also disclosed are methods of using the devices in various electrochemical reactions.

Abstract: An energy storage system, including: a first switch and a first inductor connected in series and connected to a positive electrode of an external DC system; a pre-stage bidirectional buck-boost conversion circuit, the circuit including a first terminal, a second terminal, and a third terminal; a pre-charge circuit, a fourth switch, and a super-capacitor sequentially connected in series, two terminals of a series structure resulting therefrom being connected to the third terminal of the pre-stage bidirectional buck-boost conversion circuit and the negative electrode of the external DC system, respectively; a post-stage bidirectional buck-boost conversion circuit, the circuit including a first terminal, a second terminal, and a third terminal; and a battery, a second switch, and a second inductor connected in series.

Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.

Abstract: An automation component includes a display having addressable locations in an array for display of data, and control circuitry that is configured to control the display. In a first mode, the control circuitry controls illumination of one or more individual locations of the display in the array for conveying individual data corresponding to the individual locations. In a second mode, the control circuitry controls illumination of two or more individual locations in the array to display an amalgamated alphanumeric character.

Abstract: An information processing apparatus includes a reception unit that receives a progress condition of a group printing job constituted by plural printing jobs, and a presentation unit that presents the progress condition of the group printing job in accordance with an item for presenting the progress condition.

Abstract: The disclosure provides a catalyst system and a method for ethylene oligomerization using this. The catalyst system contains: ligand a, containing carbene groups of imidazole ring type; transition metal compound b, that is one of IVB˜VIII group metal compounds; activator c, that is a compound containing III A group metals; the ligand a contains at least one group as shown in general formula I: in which, bridging group A contains a main chain including alkyl, alkenyl, aryl groups or the combination of them and the first heteratom; E is a linear or cyclic group containing the second heteroatom; R is a hydrocarbyl group. The catalyst system is especially used for trimerization and tetramerization of ethylene. The catalyst system has high selectivity for 1-hexene and 1-octene, low selectivity for 1-butene and I-C10+, and the total percent content of C6˜C8 linear ??-olefin in the product is more than 90% by mass.

Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.

Abstract: A print management apparatus includes a memory that stores settings information of a print job, and printer information, a display controller that controls a display to simultaneously display a print job list representing a list of print jobs, and a printer list representing a list of printers, and a receiving unit that receives an input to the print job list displayed on the display. The display controller changes, in response to reception by the receiving unit of an input to select a print job displayed in the print job list, the display order of printers in the printer list by use of the settings information of the selected print job and the printer information. The receiving unit receives, from a screen displayed on the display and in which the changing of the display order is reflected, an input to select a destination printer to which to transmit a print job.

Abstract: An energy storage system, including: a first switch and a first inductor connected in series and connected to a positive electrode of an external DC system; a pre-stage bidirectional buck-boost conversion circuit, the circuit including a first terminal, a second terminal, and a third terminal; a pre-charge circuit, a fourth switch, and a super-capacitor sequentially connected in series, two terminals of a series structure resulting therefrom being connected to the third terminal of the pre-stage bidirectional buck-boost conversion circuit and the negative electrode of the external DC system, respectively; a post-stage bidirectional buck-boost conversion circuit, the circuit including a first terminal, a second terminal, and a third terminal; and a battery, a second switch, and a second inductor connected in series.

Abstract: A mobile device charger with mounting ability is disclosed. An attachment seat is attached to a mobile device, the attachment seat has a charging cable and charging plug that can be plugged into the charge port of mobile device. The attachment seat has an electrode section and a magnet section to interact with a charger mounting support that has a matching charging head with an electrode section and a magnet section. The charger mounting support also has a rotation section and a power converting configuration and port for power supply port.

Abstract: A print management apparatus includes a memory that stores settings information of a print job, and printer information, a display controller that controls a display to simultaneously display a print job list representing a list of print jobs, and a printer list representing a list of printers, and a receiving unit that receives an input to the print job list displayed on the display. The display controller changes, in response to reception by the receiving unit of an input to select a print job displayed in the print job list, the display order of printers in the printer list by use of the settings information of the selected print job and the printer information. The receiving unit receives, from a screen displayed on the display and in which the changing of the display order is reflected, an input to select a destination printer to which to transmit a print job.

Abstract: Compounds of Formulae Ia, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.

Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

Abstract: A mobile device charger with mounting ability is disclosed. An attachment seat is attached to a mobile device, the attachment seat has a charging cable and charging plug that can be plugged into the charge port of mobile device. The attachment seat has an electrode section and a magnet section to interact with a charger mounting support that has a matching charging head with an electrode section and a magnet section. The charger mounting support also has a rotation section and a power converting configuration and port for power supply port.

Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.

Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.